A metiléntetrahidrofolát-reduktáz (MTHFR) C677T polimorfizmus klinikai jelentôsége a metasztatikus colorectalis daganatok 5-fluoropirimidin-alapú kezelésében.

Translated title of the contribution: The clinical importance of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the 5-fluoropyrimidine-based therapy of metastatic colorectal tumours

Barna Budai, Erika Hitre, Vilmos Adleff, Ferenc Czeglédi, Fruzsina Gyergyay, István Láng, Judit Kralovánszky

Research output: Contribution to journalArticle

Abstract

The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.

Original languageHungarian
Pages (from-to)253-257
Number of pages5
JournalMagyar Onkologia
Volume48
Issue number3
Publication statusPublished - 2004

Fingerprint

Methylenetetrahydrofolate Reductase (NADPH2)
Colorectal Neoplasms
Genotype
Therapeutics
Survival
Group Psychotherapy
5-fluoropyrimidine
Restriction Fragment Length Polymorphisms
Alleles
Polymerase Chain Reaction

ASJC Scopus subject areas

  • Cancer Research

Cite this

A metiléntetrahidrofolát-reduktáz (MTHFR) C677T polimorfizmus klinikai jelentôsége a metasztatikus colorectalis daganatok 5-fluoropirimidin-alapú kezelésében. / Budai, Barna; Hitre, Erika; Adleff, Vilmos; Czeglédi, Ferenc; Gyergyay, Fruzsina; Láng, István; Kralovánszky, Judit.

In: Magyar Onkologia, Vol. 48, No. 3, 2004, p. 253-257.

Research output: Contribution to journalArticle

@article{cd3be58bf6654bdf9032237949a1606c,
title = "A metil{\'e}ntetrahidrofol{\'a}t-redukt{\'a}z (MTHFR) C677T polimorfizmus klinikai jelent{\^o}s{\'e}ge a metasztatikus colorectalis daganatok 5-fluoropirimidin-alap{\'u} kezel{\'e}s{\'e}ben.",
abstract = "The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.",
author = "Barna Budai and Erika Hitre and Vilmos Adleff and Ferenc Czegl{\'e}di and Fruzsina Gyergyay and Istv{\'a}n L{\'a}ng and Judit Kralov{\'a}nszky",
year = "2004",
language = "Hungarian",
volume = "48",
pages = "253--257",
journal = "Magyar Onkologia",
issn = "0025-0244",
publisher = "Akademiai Kiado",
number = "3",

}

TY - JOUR

T1 - A metiléntetrahidrofolát-reduktáz (MTHFR) C677T polimorfizmus klinikai jelentôsége a metasztatikus colorectalis daganatok 5-fluoropirimidin-alapú kezelésében.

AU - Budai, Barna

AU - Hitre, Erika

AU - Adleff, Vilmos

AU - Czeglédi, Ferenc

AU - Gyergyay, Fruzsina

AU - Láng, István

AU - Kralovánszky, Judit

PY - 2004

Y1 - 2004

N2 - The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.

AB - The authors investigated the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in 101 metastatic colorectal cancer patients treated with 5-fluoropyrimidine-based therapy and in 196 healthy individuals by PCR-RFLP method. There was no significant difference in genotype distribution of patients and healthy controls, and between subgroups investigated according to clinical parameters (age, gender, tumor location, grade and treatment type). However, after a 3-30 (median 18.5) months follow-up the survival of patients with T allele proved to be better than that of patients with wild type (CC) genotype (p=0.036). In case of CT and TT genotypes the survival of patients receiving only first line therapy was significantly shorter than that of patients receiving more lines of treatment (p=0.015). Determination of MTHFR C677T polymorphism has prognostic value in case of patients with metastatic colorectal cancer receiving 5-fluoropyrimidine-based therapy, and may help in designing the individual (group) tailored therapy.

UR - http://www.scopus.com/inward/record.url?scp=21644450232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644450232&partnerID=8YFLogxK

M3 - Article

C2 - 15520876

VL - 48

SP - 253

EP - 257

JO - Magyar Onkologia

JF - Magyar Onkologia

SN - 0025-0244

IS - 3

ER -